<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <title>Research • Stanfield Lab</title>
  <meta name="description" content="Stanfield Lab at LSU SVM: Viral oncology and guinea-pig models of virus-associated cancers.">
  <link rel="icon" href="assets/favicon.svg" type="image/svg+xml">
  <link rel="stylesheet" href="assets/styles.css">
</head>
<body>
  <a class="skip-link" href="#main">Skip to content</a>

<header class="site-header" role="banner">
  <div class="container header-wrap">
    <a class="brand" href="index.html" aria-label="Stanfield Lab home">
      <img src="assets/stanfield-lab-logo.svg" alt="Stanfield Lab" class="brand-img">
    </a>
    <nav aria-label="Primary">
      <button id="navToggle" class="nav-toggle" aria-expanded="false" aria-controls="primaryNav">Menu</button>
      <ul id="primaryNav" class="nav-list">
        <li><a href="index.html">Home</a></li>
        <li><a href="research.html" aria-current="page">Research</a></li>
        <li><a href="people.html">People</a></li>
        <li><a href="publications.html">Publications</a></li>
        <li><a href="news.html">News</a></li>
        <li><a href="opportunities.html">Opportunities</a></li>
        <li><a href="contact.html">Contact</a></li>
      </ul>
    </nav>
    <button id="themeToggle" class="theme-toggle" aria-label="Toggle dark mode">◐</button>
  </div>
</header>

<main id="main" class="container">
  <h1>Research</h1>

  <p>
    The Stanfield Lab investigates how oncogenic herpesviruses initiate infection,
    evade host defenses, and drive cancer development. Our central mission is to
    create and refine <strong>immune-competent guinea pig models</strong> that bridge
    the gap between basic virology and translational medicine. By combining primary
    cell culture, in vivo pathogenesis studies, and advanced genomics, we aim to
    uncover how viruses such as <strong>Kaposi’s sarcoma–associated herpesvirus (KSHV)</strong>
    and <strong>Epstein–Barr virus (EBV)</strong> establish infection and promote tumorigenesis.
  </p>

  <p>
    Guinea pigs provide a uniquely valuable system: their immune and physiological
    responses often parallel those of humans more closely than traditional murine
    models. We leverage this platform to model virus–host interactions, test
    therapeutic strategies, and expand the toolkit for studying host-restricted
    pathogens that have lacked tractable small-animal models.
  </p>

  <h2>Current focus areas</h2>
  <ul class="checklist">
    <li>
      <strong>Innate sensing and viral evasion.</strong>
      Defining how KSHV activates and subverts the <em>IRF7</em>, <em>MDA5</em>, and
      RIG-I pathways in guinea pig cells, and identifying viral genes that interfere
      with these sensors.
    </li>
    <!-- Drop this right under your first paragraph in research.html -->
<figure class="research-graphic innate-fig" role="group" aria-labelledby="fig-innate-title fig-innate-desc">
  <svg viewBox="0 0 1100 560" xmlns="http://www.w3.org/2000/svg" aria-describedby="fig-innate-desc">
    <title id="fig-innate-title">Innate sensing via MDA5 → MAVS → IRF7: activation in guinea pig vs KSHV suppression in human</title>
    <desc id="fig-innate-desc">
      Left panel (Guinea Pig): dsRNA sensed by MDA5 signals through MAVS to IRF7 and IFN. KSHV antagonists may be ineffective due to miRNA seed mismatch in gpIFIH1 and vIRF-3
      binding interface divergence with gpIRF7. Right panel (Human): KSHV miRNA represses MDA5/IFIH1 transcripts and vIRF-3 (K10.5) inhibits IRF7, dampening IFN output.
    </desc>

    <!-- ========== MARKERS ========== -->
    <defs>
      <!-- Arrow for activation -->
      <marker id="arrow-activ" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto-start-reverse">
        <path d="M 0 0 L 10 5 L 0 10 z" fill="#1fb6ff"/>
      </marker>
      <!-- Arrow for neutral/gray flow -->
      <marker id="arrow-neutral" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto-start-reverse">
        <path d="M 0 0 L 10 5 L 0 10 z" fill="#9aa3af"/>
      </marker>
      <!-- Blunt inhibitor (T-bar) -->
      <marker id="tbar" viewBox="0 0 12 12" refX="2" refY="6" markerWidth="10" markerHeight="10" orient="auto">
        <path d="M2 0 V12" stroke="#ef4444" stroke-width="3"/>
      </marker>
      <!-- Pill/capsule node -->
      <linearGradient id="node-grad" x1="0" x2="1" y1="0" y2="1">
        <stop offset="0%" stop-color="#0ea5e9"/>
        <stop offset="100%" stop-color="#2dd4bf"/>
      </linearGradient>
      <!-- Soft shadow -->
      <filter id="soft" x="-30%" y="-30%" width="160%" height="160%">
        <feDropShadow dx="0" dy="2" stdDeviation="6" flood-color="#000" flood-opacity="0.12"/>
      </filter>
    </defs>

    <!-- ========== PANELS ========== -->
    <!-- Left panel background -->
    <rect x="30" y="70" width="500" height="420" rx="18" fill="#f0f9ff" stroke="#94a3b8"/>
    <text x="280" y="50" text-anchor="middle" font-size="28" font-weight="700" fill="#0f172a">Guinea Pig</text>

    <!-- Right panel background -->
    <rect x="570" y="70" width="500" height="420" rx="18" fill="#f8fafc" stroke="#94a3b8"/>
    <text x="820" y="50" text-anchor="middle" font-size="28" font-weight="700" fill="#0f172a">Human</text>

    <!-- Panel divider -->
    <line x1="550" y1="70" x2="550" y2="490" stroke="#94a3b8" stroke-width="2"/>

    <!-- ========== LEFT: GUINEA PIG (ACTIVE) ========== -->
    <!-- Labels -->
    <text x="80" y="110" font-size="16" fill="#334155">dsRNA (viral)</text>

    <!-- dsRNA icon -->
    <path d="M90 130 C110 120,130 140,150 130
             M90 140 C110 130,130 150,150 140"
          stroke="#2563eb" stroke-width="3" fill="none"/>

    <!-- Nodes: MDA5, MAVS, IRF7, IFN -->
    <!-- Node helper: rounded pill -->
    <!-- MDA5 -->
    <g filter="url(#soft)">
      <rect x="210" y="120" width="120" height="40" rx="20" fill="url(#node-grad)"/>
      <text x="270" y="146" text-anchor="middle" font-size="18" font-weight="700" fill="#fff">MDA5</text>
    </g>
    <!-- MAVS -->
    <g filter="url(#soft)">
      <rect x="210" y="210" width="120" height="40" rx="20" fill="url(#node-grad)"/>
      <text x="270" y="236" text-anchor="middle" font-size="18" font-weight="700" fill="#fff">MAVS</text>
    </g>
    <!-- IRF7 -->
    <g filter="url(#soft)">
      <rect x="210" y="300" width="120" height="40" rx="20" fill="url(#node-grad)"/>
      <text x="270" y="326" text-anchor="middle" font-size="18" font-weight="700" fill="#fff">IRF7</text>
    </g>
    <!-- IFN -->
    <g filter="url(#soft)">
      <rect x="210" y="390" width="120" height="40" rx="20" fill="#10b981"/>
      <text x="270" y="416" text-anchor="middle" font-size="18" font-weight="700" fill="#ffffff">IFN</text>
    </g>

    <!-- Activation arrows -->
    <line x1="150" y1="135" x2="210" y2="140" stroke="#1fb6ff" stroke-width="6" marker-end="url(#arrow-activ)"/>
    <line x1="270" y1="160" x2="270" y2="210" stroke="#1fb6ff" stroke-width="6" marker-end="url(#arrow-activ)"/>
    <line x1="270" y1="250" x2="270" y2="300" stroke="#1fb6ff" stroke-width="6" marker-end="url(#arrow-activ)"/>
    <line x1="270" y1="340" x2="270" y2="390" stroke="#1fb6ff" stroke-width="6" marker-end="url(#arrow-activ)"/>

    <!-- Callouts: why antagonism may fail in guinea pig -->
    <g>
      <rect x="350" y="118" width="160" height="66" rx="10" fill="#ecfeff" stroke="#22d3ee"/>
      <text x="430" y="138" text-anchor="middle" font-size="13" fill="#155e75">KSHV miRNA</text>
      <text x="430" y="156" text-anchor="middle" font-size="12" fill="#155e75">seed mismatch in gpIFIH1</text>
      <text x="430" y="172" text-anchor="middle" font-size="12" fill="#155e75">reduced MDA5 repression</text>
      <line x1="350" y1="150" x2="330" y2="150" stroke="#22d3ee" stroke-width="3" marker-end="url(#arrow-neutral)"/>
    </g>

    <g>
      <rect x="350" y="298" width="160" height="66" rx="10" fill="#ecfeff" stroke="#22d3ee"/>
      <text x="430" y="318" text-anchor="middle" font-size="13" fill="#155e75">K10.5 (vIRF-3)</text>
      <text x="430" y="336" text-anchor="middle" font-size="12" fill="#155e75">binding interface divergence</text>
      <text x="430" y="352" text-anchor="middle" font-size="12" fill="#155e75">IRF7 not efficiently inhibited</text>
      <line x1="350" y1="330" x2="330" y2="320" stroke="#22d3ee" stroke-width="3" marker-end="url(#arrow-neutral)"/>
    </g>

    <!-- ========== RIGHT: HUMAN (SUPPRESSED) ========== -->
    <!-- dsRNA label -->
    <text x="620" y="110" font-size="16" fill="#334155">dsRNA (viral)</text>
    <path d="M630 130 C650 120,670 140,690 130
             M630 140 C650 130,670 150,690 140"
          stroke="#475569" stroke-width="3" fill="none"/>

    <!-- Nodes: gray tone -->
    <!-- MDA5 -->
    <g filter="url(#soft)">
      <rect x="750" y="120" width="120" height="40" rx="20" fill="#94a3b8"/>
      <text x="810" y="146" text-anchor="middle" font-size="18" font-weight="700" fill="#fff">MDA5</text>
    </g>
    <!-- MAVS -->
    <g filter="url(#soft)">
      <rect x="750" y="210" width="120" height="40" rx="20" fill="#94a3b8"/>
      <text x="810" y="236" text-anchor="middle" font-size="18" font-weight="700" fill="#fff">MAVS</text>
    </g>
    <!-- IRF7 -->
    <g filter="url(#soft)">
      <rect x="750" y="300" width="120" height="40" rx="20" fill="#94a3b8"/>
      <text x="810" y="326" text-anchor="middle" font-size="18" font-weight="700" fill="#fff">IRF7</text>
    </g>
    <!-- IFN (dim) -->
    <g filter="url(#soft)">
      <rect x="750" y="390" width="120" height="40" rx="20" fill="#d1d5db"/>
      <text x="810" y="416" text-anchor="middle" font-size="18" font-weight="700" fill="#374151">IFN</text>
    </g>

    <!-- Neutral/gray flow with inhibition -->
    <line x1="690" y1="135" x2="750" y2="140" stroke="#9aa3af" stroke-width="6" marker-end="url(#arrow-neutral)"/>
    <line x1="810" y1="160" x2="810" y2="210" stroke="#9aa3af" stroke-width="6" marker-end="url(#arrow-neutral)"/>
    <line x1="810" y1="250" x2="810" y2="300" stroke="#9aa3af" stroke-width="6" marker-end="url(#arrow-neutral)"/>
    <line x1="810" y1="340" x2="810" y2="390" stroke="#9aa3af" stroke-width="6" marker-end="url(#arrow-neutral)"/>

    <!-- KSHV miRNA inhibiting MDA5 transcripts -->
    <g>
      <rect x="900" y="112" width="170" height="70" rx="10" fill="#fee2e2" stroke="#ef4444"/>
      <text x="985" y="136" text-anchor="middle" font-size="14" font-weight="700" fill="#991b1b">KSHV miRNA</text>
      <text x="985" y="156" text-anchor="middle" font-size="12" fill="#991b1b">targets IFIH1 (MDA5) mRNA</text>
      <line x1="900" y1="147" x2="870" y2="147" stroke="#ef4444" stroke-width="4" marker-end="url(#tbar)"/>
    </g>

    <!-- vIRF-3 (K10.5) inhibiting IRF7 -->
    <g>
      <rect x="900" y="292" width="170" height="70" rx="10" fill="#fee2e2" stroke="#ef4444"/>
      <text x="985" y="316" text-anchor="middle" font-size="14" font-weight="700" fill="#991b1b">K10.5 (vIRF-3)</text>
      <text x="985" y="336" text-anchor="middle" font-size="12" fill="#991b1b">binds & inhibits IRF7</text>
      <line x1="900" y1="327" x2="870" y2="320" stroke="#ef4444" stroke-width="4" marker-end="url(#tbar)"/>
    </g>

  </svg>

  <figcaption class="muted">
    MDA5/RIG-I–like sensing in guinea pig vs human during KSHV infection. Left: robust activation to IFN (hypothesized reduced antagonism via miRNA seed mismatch in gpIFIH1 and
    weaker vIRF-3 binding to gpIRF7). Right: KSHV miRNAs repress MDA5/IFIH1 transcripts and K10.5/vIRF-3 inhibits IRF7, dampening IFN output.
  </figcaption>
</figure>

<style>
  /* Optional styling; you can move to assets/styles.css */
  .research-graphic { margin: 2rem auto; text-align: center; }
  .research-graphic svg { max-width: 100%; height: auto; }
  .research-graphic .muted { color: #555; font-size: 0.95rem; margin-top: .5rem; }
</style>

    <li>
      <strong>Endothelial infection and tumorigenesis.</strong>
      Establishing cultures of guinea pig endothelial cells and modeling how
      KSHV-driven transformation leads to vascularized tumors, both in immunodeficient
      mice and in immunosuppressed strain 2 guinea pigs.
    </li>
    <figure class="research-graphic kshv-endo-fig" role="group" aria-labelledby="fig-kshv-endo-title fig-kshv-endo-desc">
  <svg viewBox="0 0 1180 680" xmlns="http://www.w3.org/2000/svg" aria-describedby="fig-kshv-endo-desc">
    <title id="fig-kshv-endo-title">KSHV-driven endothelial transformation: entry, signaling, latency programs, and angiogenic/paracrine drivers</title>
    <desc id="fig-kshv-endo-desc">
      Left: KSHV attaches to heparan sulfate and engages integrins (αVβ3/α3β1) and EphA2, activating FAK/Src and PI3K–AKT/MAPK signaling.
      Right: Latency programs (LANA, vCyclin–CDK6, vFLIP, KSHV miRNAs, K1) and paracrine/angiogenic drivers (vIL-6, vGPCR/ORF74 → VEGF) promote endothelial transformation to KS-like lesions.
    </desc>

    <defs>
      <linearGradient id="panelL" x1="0" x2="0" y1="0" y2="1"><stop offset="0%" stop-color="#e0f2fe"/><stop offset="100%" stop-color="#bae6fd"/></linearGradient>
      <linearGradient id="panelR" x1="0" x2="0" y1="0" y2="1"><stop offset="0%" stop-color="#f8fafc"/><stop offset="100%" stop-color="#e5e7eb"/></linearGradient>
      <linearGradient id="vessel" x1="0" x2="0" y1="0" y2="1"><stop offset="0%" stop-color="#fecaca"/><stop offset="100%" stop-color="#ef4444"/></linearGradient>
      <filter id="soft" x="-30%" y="-30%" width="160%" height="160%"><feDropShadow dx="0" dy="2" stdDeviation="6" flood-color="#000" flood-opacity="0.12"/></filter>
      <marker id="arrow" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0 L10 5 L0 10Z" fill="#0ea5e9"/></marker>
      <marker id="arrow-red" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0 L10 5 L0 10Z" fill="#ef4444"/></marker>
      <marker id="arrow-green" viewBox="0 0 10 10" refX="9" refY="5" markerWidth="8" markerHeight="8" orient="auto"><path d="M0 0 L10 5 L0 10Z" fill="#10b981"/></marker>
    </defs>

    <!-- column headers -->
    <text x="295" y="40" text-anchor="middle" font-size="28" font-weight="700" fill="#0f172a">Entry & early signaling</text>
    <text x="885" y="40" text-anchor="middle" font-size="28" font-weight="700" fill="#0f172a">Latency & paracrine tumorigenesis</text>

    <!-- panels -->
    <rect x="40"  y="60" width="510" height="430" rx="22" fill="url(#panelL)" stroke="#93c5fd" filter="url(#soft)"/>
    <rect x="630" y="60" width="510" height="430" rx="22" fill="url(#panelR)" stroke="#cbd5e1" filter="url(#soft)"/>
    <line x1="600" y1="60" x2="600" y2="490" stroke="#cbd5e1" stroke-width="2"/>

    <!-- LEFT: blood vessel + endothelium belt -->
    <g>
      <rect x="70" y="120" width="450" height="310" rx="22" fill="url(#vessel)" stroke="#ef4444" stroke-width="3" filter="url(#soft)"/>
      <rect x="70" y="110" width="450" height="40" rx="18" fill="#bbf7d0" stroke="#10b981" stroke-width="2"/>
      <text x="295" y="102" text-anchor="middle" font-size="14" fill="#065f46">Endothelial monolayer</text>
      <g fill="#059669">
        <circle cx="120" cy="130" r="6"/><circle cx="180" cy="130" r="6"/><circle cx="240" cy="130" r="6"/>
        <circle cx="300" cy="130" r="6"/><circle cx="360" cy="130" r="6"/><circle cx="420" cy="130" r="6"/>
      </g>
    </g>

    <!-- KSHV particles approaching + arrows (kept clear of labels) -->
    <g>
      <g fill="#2563eb" stroke="#1e3a8a" stroke-width="2">
        <circle cx="140" cy="210" r="12"/><circle cx="230" cy="235" r="12"/><circle cx="330" cy="210" r="12"/><circle cx="420" cy="240" r="12"/>
      </g>
      <line x1="140" y1="198" x2="140" y2="132" stroke="#0ea5e9" stroke-width="4" marker-end="url(#arrow)"/>
      <line x1="230" y1="223" x2="230" y2="132" stroke="#0ea5e9" stroke-width="4" marker-end="url(#arrow)"/>
      <line x1="330" y1="198" x2="330" y2="132" stroke="#0ea5e9" stroke-width="4" marker-end="url(#arrow)"/>
      <line x1="420" y1="228" x2="420" y2="132" stroke="#0ea5e9" stroke-width="4" marker-end="url(#arrow)"/>
      <text x="295" y="265" text-anchor="middle" font-size="14" fill="#1e40af">KSHV particles attach & enter</text>
    </g>

    <!-- receptor/signaling card -->
    <g>
      <rect x="100" y="290" width="380" height="70" rx="12" fill="#eef2ff" stroke="#6366f1"/>
      <text x="290" y="315" text-anchor="middle" font-size="14" font-weight="700" fill="#3730a3">Heparan sulfate → Integrins (αVβ3/α3β1) & EphA2</text>
      <text x="290" y="336" text-anchor="middle" font-size="13" fill="#3730a3">Activates FAK/Src → PI3K–AKT & MAPK (entry/survival/proliferation)</text>
    </g>

    <!-- compact pathway row (boxed, no overlap) -->
    <g>
      <rect x="110" y="372" width="110" height="38" rx="10" fill="#e0f2fe" stroke="#0ea5e9"/>
      <text x="165" y="395" text-anchor="middle" font-size="14" fill="#075985">FAK/Src</text>
      <line x1="220" y1="391" x2="270" y2="391" stroke="#0ea5e9" stroke-width="4" marker-end="url(#arrow)"/>
      <rect x="270" y="372" width="130" height="38" rx="10" fill="#dcfce7" stroke="#10b981"/>
      <text x="335" y="395" text-anchor="middle" font-size="14" fill="#065f46">PI3K–AKT</text>
      <line x1="220" y1="408" x2="220" y2="446" stroke="#0ea5e9" stroke-width="4" marker-end="url(#arrow)"/>
      <rect x="160" y="446" width="120" height="38" rx="10" fill="#fee2e2" stroke="#ef4444"/>
      <text x="220" y="469" text-anchor="middle" font-size="14" fill="#991b1b">MAPK</text>
    </g>

    <!-- RIGHT: latency modules laid out in a grid (no overlaps) -->
    <!-- row 1 -->
    <g>
      <rect x="660" y="100" width="150" height="46" rx="12" fill="#fef3c7" stroke="#f59e0b"/>
      <text x="735" y="127" text-anchor="middle" font-size="15" font-weight="700" fill="#92400e">LANA</text>
      <text x="735" y="145" text-anchor="middle" font-size="12" fill="#92400e">episome tethering; p53/RB</text>

      <rect x="830" y="100" width="190" height="46" rx="12" fill="#e0f2fe" stroke="#0ea5e9"/>
      <text x="925" y="127" text-anchor="middle" font-size="15" font-weight="700" fill="#075985">vCyclin–CDK6</text>
      <text x="925" y="145" text-anchor="middle" font-size="12" fill="#075985">cell-cycle drive</text>

      <rect x="1040" y="100" width="80" height="46" rx="12" fill="#dcfce7" stroke="#10b981"/>
      <text x="1080" y="127" text-anchor="middle" font-size="14" font-weight="700" fill="#065f46">K1</text>
      <text x="1080" y="145" text-anchor="middle" font-size="11" fill="#065f46">PI3K</text>
    </g>

    <!-- row 2 -->
    <g>
      <rect x="660" y="170" width="150" height="46" rx="12" fill="#fee2e2" stroke="#ef4444"/>
      <text x="735" y="197" text-anchor="middle" font-size="15" font-weight="700" fill="#991b1b">vFLIP</text>
      <text x="735" y="215" text-anchor="middle" font-size="12" fill="#991b1b">NF-κB survival</text>

      <rect x="830" y="170" width="190" height="46" rx="12" fill="#eef2ff" stroke="#6366f1"/>
      <text x="925" y="197" text-anchor="middle" font-size="15" font-weight="700" fill="#3730a3">KSHV miRNAs</text>
      <text x="925" y="215" text-anchor="middle" font-size="12" fill="#3730a3">host/viral gene tuning</text>

      <rect x="1040" y="170" width="80" height="46" rx="12" fill="#fef3c7" stroke="#f59e0b"/>
      <text x="1080" y="197" text-anchor="middle" font-size="14" font-weight="700" fill="#92400e">Episome</text>
      <text x="1080" y="215" text-anchor="middle" font-size="11" fill="#92400e">latency</text>
    </g>

    <!-- row 3: paracrine drivers -->
    <g>
      <rect x="660" y="250" width="110" height="46" rx="12" fill="#fef3c7" stroke="#f59e0b"/>
      <text x="715" y="277" text-anchor="middle" font-size="15" font-weight="700" fill="#92400e">vIL-6</text>

      <rect x="780" y="250" width="150" height="46" rx="12" fill="#fef3c7" stroke="#f59e0b"/>
      <text x="855" y="277" text-anchor="middle" font-size="15" font-weight="700" fill="#92400e">vGPCR (ORF74)</text>

      <rect x="940" y="250" width="180" height="46" rx="12" fill="#fee2e2" stroke="#ef4444"/>
      <text x="1030" y="277" text-anchor="middle" font-size="15" font-weight="700" fill="#991b1b">VEGF / angiogenesis</text>

      <line x1="715" y1="296" x2="1030" y2="296" stroke="#f59e0b" stroke-width="4" marker-end="url(#arrow-red)"/>
      <line x1="855" y1="296" x2="1030" y2="296" stroke="#f59e0b" stroke-width="4" marker-end="url(#arrow-red)"/>
    </g>

    <!-- row 4: lesion card (kept separate so it doesn't cover labels) -->
    <g>
      <rect x="870" y="320" width="270" height="120" rx="16" fill="#ffe4e6" stroke="#fb7185" filter="url(#soft)"/>
      <text x="1005" y="350" text-anchor="middle" font-size="16" font-weight="700" fill="#9f1239">KS-like spindle cell lesion</text>
      <text x="1005" y="370" text-anchor="middle" font-size="12" fill="#9f1239">vascularized nodule; endothelial origin</text>
      <line x1="1030" y1="296" x2="1030" y2="320" stroke="#ef4444" stroke-width="4" marker-end="url(#arrow-red)"/>
      <line x1="925" y1="216" x2="925" y2="320" stroke="#ef4444" stroke-width="4" marker-end="url(#arrow-red)"/>
      <line x1="735" y1="216" x2="735" y2="320" stroke="#ef4444" stroke-width="4" marker-end="url(#arrow-red)"/>
      <line x1="925" y1="146" x2="925" y2="320" stroke="#ef4444" stroke-width="4" marker-end="url(#arrow-red)"/>
    </g>

    <!-- legend -->
    <g>
      <rect x="40" y="520" width="1100" height="44" rx="10" fill="#f8fafc" stroke="#cbd5e1"/>
      <rect x="60"  y="530" width="160" height="24" rx="6" fill="#eef2ff" stroke="#6366f1"/>
      <text x="140" y="547" text-anchor="middle" font-size="12" fill="#1f2937">Entry receptors & early signaling</text>

      <rect x="235" y="530" width="200" height="24" rx="6" fill="#e0f2fe" stroke="#0ea5e9"/>
      <text x="335" y="547" text-anchor="middle" font-size="12" fill="#1f2937">PI3K–AKT / MAPK pathway modules</text>

      <rect x="450" y="530" width="210" height="24" rx="6" fill="#fef3c7" stroke="#f59e0b"/>
      <text x="555" y="547" text-anchor="middle" font-size="12" fill="#1f2937">Latency & paracrine viral genes</text>

      <rect x="675" y="530" width="170" height="24" rx="6" fill="#fee2e2" stroke="#ef4444"/>
      <text x="760" y="547" text-anchor="middle" font-size="12" fill="#1f2937">Angiogenesis output (VEGF)</text>

      <rect x="860" y="530" width="250" height="24" rx="6" fill="#ffe4e6" stroke="#fb7185"/>
      <text x="985" y="547" text-anchor="middle" font-size="12" fill="#1f2937">KS-like lesion (spindle cell, vascularized)</text>
    </g>

    <!-- knowledge box: “What’s known” -->
    <g>
      <rect x="40" y="580" width="1100" height="70" rx="12" fill="#f1f5f9" stroke="#cbd5e1"/>
      <text x="60" y="603" font-size="13" font-weight="700" fill="#0f172a">Known KSHV drivers in endothelium:</text>
      <text x="60" y="623" font-size="12" fill="#334155">Entry via heparan sulfate + integrins + EphA2 → FAK/Src → PI3K–AKT/MAPK; Latency: LANA (episome, p53/RB), vCyclin–CDK6 (cycle), vFLIP (NF-κB), KSHV miRNAs & K1 (PI3K); Paracrine: vIL-6, vGPCR → VEGF/angiogenesis → KS-like lesions.</text>
    </g>
  </svg>

  <figcaption class="muted">
    KSHV transforms endothelial cells through receptor-mediated entry and acute signaling (FAK/Src → PI3K–AKT/MAPK), durable latency programs (LANA, vCyclin–CDK6, vFLIP, KSHV miRNAs, K1),
    and paracrine/angiogenic drivers (vIL-6, vGPCR→VEGF), culminating in KS-like spindle cell, vascular lesions.
  </figcaption>
</figure>

<style>
  .research-graphic { margin: 2rem auto; text-align: center; }
  .research-graphic svg { max-width: 100%; height: auto; }
  .research-graphic .muted { color: #555; font-size: 0.95rem; margin-top: .5rem; }
</style>

    <li>
      <strong>Syngeneic lymphoma model.</strong>
      Characterizing the L2C guinea pig lymphoma line using genomics and single-cell
      RNA sequencing, and positioning it as an analog for human mantle cell lymphoma
      and CLL to test next-generation therapies such as BTK inhibitors.
    </li>
    <li>
      <strong>Comparative virology and viral adaptation.</strong>
      Exploring how related herpesviruses (e.g., rhesus rhadinovirus, guinea pig
      herpes-like viruses) adapt to new hosts, with the goal of engineering
      guinea pig–adapted strains of EBV and KSHV.
    </li>
    <li>
      <strong>Preclinical testing.</strong>
      Using our models to evaluate antivirals, live-attenuated vaccines, and
      epigenetic modulators such as HDAC inhibitors and G-quadruplex stabilizers
      for their ability to alter viral latency, immune responses, and disease
      outcomes.
    </li>
    <li>
      <strong>Single-cell and systems approaches.</strong>
      Applying single-cell RNA sequencing and pathway analysis to dissect how
      infected immune and tumor cell populations respond in vivo, and to map viral
      and host transcriptional programs during infection.
    </li>
  </ul>

  <p>
    Together, these efforts define a comprehensive program in
    <strong>viral oncology</strong>: connecting molecular mechanisms of viral
    pathogenesis to clinically relevant animal models. By expanding the guinea
    pig as a small-animal model, we are working to provide the research
    community with new tools for understanding—and ultimately intervening in—
    virus-associated cancers.
  </p>
</main>

<footer class="site-footer" role="contentinfo">
  <div class="container footer-grid">
    <div class="footer-brand">
      <img src="assets/stanfield-lab-icon.svg" alt="Stanfield Lab icon" class="footer-logo">
      <div>
        <h3>Stanfield Lab</h3>
        <p>Viral Oncology • Small-Animal Models • Translational Immunology</p>
      </div>
    </div>
    <div>
      <h4>Find us</h4>
      <p>
        <a href="https://www.lsu.edu/vetmed/index.php" target="_blank" rel="noopener">LSU School of Veterinary Medicine</a><br>
        Baton Rouge, LA 70803
      </p>
    </div>
    <div>
      <h4>Contact</h4>
      <p><a href="mailto:bstanf5@lsu.edu">bstanf5@lsu.edu</a></p>
    </div>
  </div>
  <div class="container footer-bottom">
    <p>© <span id="year"></span> Stanfield Lab • LSU SVM</p>
  </div>
  <script src="assets/script.js"></script>
</footer>

</body>
</html>
